Valuation
- Market cap
- —
- Revenue TTM
- $0
- Net income TTM
- $-64,470,000
- PE ratio
- —
- Forward PE
- —
- Profit margin
- —
- Debt to equity
- —
Trading
- Volume
- 700
- Avg volume
- 6,474
- Day's range
- $0.20 – $0.21
- Shares out
- —
- Stochastic %K
- 71%
- Beta
- —
- Analysts
- Strong Sell
- Price target
- —
Company profile
Jasper Therapeutics, Inc., a clinical stage biotechnology company, focuses on the design and development of therapies to treat immune-mediated diseases. It is advancing a pipeline of medicines, including KP-104, a dual-complement inhibitor that has demonstrated positive outcomes in paroxysmal nocturnal hemoglobinuria (PNH) and is under evaluation in other unmet need nephrology disorders; Briquilimab is an anti-KIT an...
Show more
Jasper Therapeutics, Inc., a clinical stage biotechnology company, focuses on the design and development of therapies to treat immune-mediated diseases. It is advancing a pipeline of medicines, including KP-104, a dual-complement inhibitor that has demonstrated positive outcomes in paroxysmal nocturnal hemoglobinuria (PNH) and is under evaluation in other unmet need nephrology disorders; Briquilimab is an anti-KIT antibody, which has demonstrated clinical results as a conditioning agent for stem cell transplant and mast cell mediated diseases, such as chronic urticarias and allergic asthma; and KP-701, a novel, dual-acting anti-CD79BxCD32B monoclonal antibody (mAb) for autoantibody-mediated disorders. The company is based in Redwood City, California.
- Phone
- 650-549-1400
- Website
- https://jaspertx.com
- Address
- 2200 Bridge Pkwy, Suite #102, Redwood City, United States
Latest news
No headlines yet.
